Trial Profile
Treatment of Steroid Refractory Gastro-intestinal Acute Graft-versus-Host disEase afteR AllogeneiC Hematopoietic Stem celL Transplantation With fEcal Microbiota tranSfer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Maa-T-013 (Primary)
- Indications Graft-versus-host disease
- Focus Proof of concept; Therapeutic Use
- Acronyms HERACLES
- Sponsors MaaT Pharma
- 26 Jul 2023 Results presented in a MaaT Pharma Media Release.
- 26 Jul 2023 According to a MaaT Pharma media release, pooled data from this study(n=24) and Expanded Access Program (n=52), in France published in the eClinicalMedicine.
- 17 Mar 2022 According to a MaaT Pharma media release, positive results from this study and its compassionate use program (EAP, n=52) will be reported in an oral presentation at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2022).